Total Utang marang Modal Accuray Inc. (ARAY)

Accuray - logo grafis emiten ARAY

Accuray Incorporated (ARAY) experienced management is successfully scaling the brand's international presence, as reflected in the price chart where the debt-to-equity ratio stands at 4.46. The company generates revenue through the sale of robotic systems and the maintenance of tumor radiation equipment. However, the business faces intense competition for government procurement and the risk of falling behind in the field of digital therapy planning.

accuray.com (ARAY): Rasio Utang marang Ekuitas saka 04.07.2022 nganti 29.10.2026
Produk dadi Accuray Incorporated

Investors must assess the balance sheet resilience of Accuray Incorporated (ARAY) against potential interest rate risks. This ratio compares total liabilities to net assets to determine the degree of financial leverage. The trend of the company's debt-to-equity ratio demonstrates the business's reliance on borrowed funds. Excessive debt load could limit the production development of CyberKnife robotic systems. The stability of this metric confirms the company's ability to scale equipment sales for oncology centers.

Analisis pesaing Accuray Incorporated

ONC (BeiGene) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Halozyme Therapeutics, Inc. (HALO)|Total Utang marang Modal RVMD|Total Utang marang Modal Ascentage Pharma Corp (AAPG)|Utang marang Ekuitas CG Oncology, Inc. CGON|URGN: Rasio Utang marang Ekuitas|Bicara Therapeutics - Total Utang marang Modal|Personalis Inc (PSNL) - Rasio Total Utang marang Ekuitas|ERAS: Total Utang marang Modal|Utang marang Modal Delcath Corp (DCTH)|Utang marang Ekuitas Y-mAbs Therapeutics|AURA: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas CADL (Candel Therapeutics)|SLS (sellaslifesciences.com) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal ACTU (Actuate Therapeutics, Inc)|CTOR - Rasio Total Utang marang Ekuitas|HURA: Rasio Total Utang marang Ekuitas|TARA - Total Utang marang Modal|Fate Therapeutics (FATE) - Utang marang Ekuitas|Aadi Bioscience - Rasio Kabeh Utang marang Dana Pribadi|TCRX (TScan Therapeutics Inc) - Total Utang marang Modal|Utang marang Modal Champions Oncology Corp CSBR|Total Utang marang Modal XBIT|Total Utang marang Modal cel-sci.com (CVM)|Total Utang marang Modal OSTX (OS Therapies)|RADX - Rasio Total Utang marang Ekuitas|Artiva - Total Utang marang Modal|Adlai Nortye Ltd. (ANL) - Rasio Total Utang marang Ekuitas|VERU (Veru Inc.) - Rasio Total Utang marang Ekuitas|tempesttx.com (TPST) - Total Utang marang Modal|Utang marang Ekuitas Xilio Therapeutics Inc|RENB: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal MURA|Total Utang marang Modal kairospharma.com (KAPA)|OnKure Therapeutics - Rasio Total Utang marang Ekuitas|CytoMed Therapeutics Ltd (GDTC) - Utang marang Modal|CRIS: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi APLM (Apollomics, Inc.)|THAR: Total Utang marang Modal|ADVB - Koefisien Total Utang marang Modal|Utang marang Ekuitas Genprex, Inc.|Rasio Utang marang Ekuitas CLDI (Calidi Bio)|Total Utang marang Modal SBFM|Rasio Total Utang marang Ekuitas xeneticbio.com XBIO|Utang marang Ekuitas Salarius SLRX|Kitov Pharma (PPBT) - Utang marang Modal|AONC - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi BGNE (beigene.com)|Checkpoint Therapeutics, Inc. (CKPT) - Utang marang Ekuitas|Utang Agregat marang Ekuitas ELEV (elevationoncology.com)|Utang marang Ekuitas iCAD Inc.|Utang marang Modal Ikena IKNA|Utang marang Ekuitas Notable Labs, Ltd. (NTBL)|VIRX (viracta.com) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal MOR (MorphoSys)|Total Utang marang Modal NAYA Biosciences Inc NAYA|AAPGV: Rasio Total Utang marang Ekuitas